MDG Boston presents… COMBINATION PRODUCTS FOR DRUG DELIVERY
*What are the opportunities and advances in drug delivery?
*What are the unique developmental challenges?
*What are the opportunities for funding?
Success requires collaboration between drug developers and device engineers. This is a challenge as these groups are accustomed to functioning under different types of regulations, design criteria, and controls.
This panel is a mix of entrepreneurs, big pharma, and biotech developers who will discuss the medical and business challenges where delivery innovations can provide a unique solution.
Entrepreneurs will discuss strategies for funding and development issues specific to drug delivery products. Speakers from big pharma and biotech will discuss challenges across the value chain of manufacturing and selling combination products globally.
Benefits of Drug/Device Combinations:
For many drugs, significant benefits could be obtained by combining the drug with a specialized delivery device, when compared to drugs which are primarily delivered by systemic means (e.g. orally, intravenously).
Advantages of Combination Products:
*Reduced dosing of expensive compounds
*More control over the delivery profile
*Greater patient convenience/compliance
The ultimate goal is to improve patient outcomes. The success of many new therapies is contingent on the development of effective delivery systems as traditional delivery methods won’t work for some compounds and biologics.
Opportunities exist for combination products to extend the patent life of existing drugs on the market:
A diverse set of scientific and engineering disciplines can converge to create elegant solutions to drug delivery problems. System level solutions may involve advanced materials, chemistry, sensors and software for monitoring and control.
Join Us for a Discussion on the Growing Opportunities for Development of
Oct 30 – Wednesday
Regis College, Fine Arts Center
To Register : https://www.mdgboston.org/events/EventDetails.aspx?id=1268607&group=
Earlybird Fees by Oct 23
Member/Alliance Partner – $35
Non-member – $45
Regis Alumni – $25
Student (member) – $10
Student (non-member) – $15
Gold Member – No Charge
Who Should Attend:
Physicians and engineers – Technological advances and development pathways
Pharma professionals, scientists and clinicians Novel – compounds with delivery challenges
Entrepreneurs and investors – Innovative business opportunities
Sales & Marketing professionals – Go-to-market strategies and pricing models for combination products.
Regulatory and clinical development – Testing, validation and monitoring of combination products.
– Michael J. Cima, PhD
Professor, Materials Science and Engineering, Massachusetts Institute of Technology
– Dan Groszmann, PhD
Principal Engineer, Device Technology Innovation Center, Amgen
– Maria Palasis, PhD
President and Chief Executive Officer, Lyra Therapeutics
– Rami Tzafriri, PhD
Director of Research and Innovation, CBSET
– Maria Shepherd – MODERATOR
President and CEO, Medi-Vantage